Oxford Biomedica new manufacturing suite approved
Oxford Biomedica
218.50p
16:34 24/04/24
Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
FTSE 250
19,719.37
17:09 24/04/24
FTSE 350
4,419.71
17:09 24/04/24
FTSE All-Share
4,374.06
16:44 24/04/24
Pharmaceuticals & Biotechnology
21,897.50
17:09 24/04/24
Approval was given by the UK Medicines & Healthcare products Regulatory Agency, the company said on Tuesday.
“Both this suite and the suite approved in September …at present will be dedicated to the manufacture of a Covid-19 viral vector vaccine candidate,” Oxford said.
“This world class facility is suitable for the manufacture of a variety of viral vectors and the approval of this fourth suite completes a phase of expansion that more than doubles Oxford Biomedica's manufacturing capacity compared to 2019, supporting further growth in revenues and partner programmes.”